Nuclear Medicine has been available since the late 1940s. However, during the last decade, the market saw the emergence of new radionuclides and the number of products under development has grown. Opportunities for development, investments, mergers and acquisitions are just ahead.
Increasing incidences of cancer and cardiac ailments, increasing awareness of people for radiopharmaceuticals and ready availability of radiopharmaceuticals are the major driving factors for the market. PET and SPECT increasing usage also propels the market to grow. However, short half life of isotopes and stringent regulations are the factors that are hindering the growth of radiopharmaceuticals worldwide.
This era opens new opportunities in the nuclear medicine landscape. The opportunities have been identified not only in the radio diagnostic area but also in therapeutic radiopharmaceuticals, with the first products scheduled to reach the market before the end of 2020. Opportunities exist for larger groups or investors to finance such development, to merge with some partners and/or to acquire companies.
In 2013 the market was dominated by Techentium-99m with about 60% of the market share, rest mostly driven by the therapeutic radiopharmaceutical which corresponds only 4%.
The market is segmented by applications( Diagnostic and Therapeutic). Diagnostic market consists of SPECT and PET radioisotopes. While, therapeutic market is segmented as Beta emitters, Alpha emitters and brachytherapy.
The U.S market is highly supported by Mo-99 production of NRU reactor (Canada). Market holds a good position in US market because of more people suffering from Cancer and cardiac diseases.
Major companies discussed in the report are Covidien , IBA Group, Lantheus Medical Imaging, Triad Isotopes, Siemens Healthcare (PETNET Solutions), NTP Radioisotopes.
What makes our report unique?
1) For gaining an exhaustive understanding of the North America nuclear medicine market.
2) Would be of assistance in providing a comprehensive analysis of the major trends and associated prospects for market growth over the coming half a decade.
3.An ideal opportunity for industry consultants, other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
4) Wide-ranging information provided about the leading market players and the major strategies adopted by them.
1.1 Nuclear medicine procedures
1.2 Major nuclear medicine products
1.3 The S-Curve of nuclear medicine
1.4 Market Matrix
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1 Definition of radiopharmaceuticals
4. Market Dynamics
4.1 Market Drivers
4.1.1 Increasing incidents of Cancer and Cardiac ailments
4.1.2 Increasing use of SPECT and PET analysis in radiopharmaceuticals
4.1.3 Increasing awareness of radiopharmaceuticals
4.1.4 Public Awareness
4.1.5 Ready availability of radiopharmaceuticals
4.2 Market Constraints
4.2.1 Shorter half life of radiopharmaceuticals
4.2.2 High capiltal investment
4.2.3 Regulatory Guidelines
4.2.4 Reimbursement issues
4.3.1 Potential radioisotopes in pipeline
4.3.2 Increasing neurological applications
4.3.3 Cyclotron based production
4.4.1 Shutdown of Nuclear reactors
5. North America Nuclear Medicine Market Segmentation
5.1 Nuclear Medicine Market, By Type of Products
5.1.1 Diagnostic Market
184.108.40.206 SPECT Radioisotopes
220.127.116.11.1 Technetium-99m (TC-99m)
18.104.22.168.2 Thallium-201 (TL-201)
22.214.171.124.3 Iodine (I-123)
126.96.36.199.4 Gallium -67( Ga-67)
188.8.131.52 PET Radioisotopes
184.108.40.206.2 Rubidium-82 (RB-82)
5.1.2 Therapeutic Market
220.127.116.11 Beta Emitters
18.104.22.168 Alpha Emitters
5.2 North america Nuclear medicine market, By applications
5.3 North america Country wise segmentation
6. COMPETITIVE LANDSCAPE
6.1 Acquisitions and mergers
6.2 New product launch
6.3 Agreements and collaborations
6.4 Market Share Analysis
7. TOP PLAYERS IN THE MARKET
7.2 IBA Group
7.3 Lantheus Medical Imaging
7.4 Triad Isotopes
7.5 Siemens Healthcare (PETNET Solutions)
7.6 NTP Radioisotopes